- PrimeC was well tolerated over 18 months, with mostly mild to moderate adverse events and no new safety signals.
- Patients receiving continuous PrimeC showed less decline in ALS Functional Rating Scale–Revised scores, particularly by month 18.
- Treatment was associated with lower rates of hospitalization, respiratory failure, or death.
- PrimeC favorably affected iron-regulatory markers and reduced ALS-associated microRNAs.
- Findings suggest potential disease-modifying effects, warranting confirmation in phase 3 trials.
Source: JAMA Neurology
